The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer

Objective: SEC23A, a gene implicated in vesicle transport, has an undefined role in the progression of gastric cancer (GC). This study aims to comprehensively characterize the clinical significance, molecular mechanisms, and therapeutic potential of SEC23A in GC. Methods: functional assays were conducted to assess the impact of SEC23A knockdown on GC cell proliferation. Results: experiments confirmed that SEC23A knockdown effectively suppressed GC cell proliferation. Conclusions: Our findings underscore the critical role of SEC23A in driving GC progression and modulating the immune landscape. SEC23A represents a promising prognostic biomarker and a novel therapeutic target for GC, potentially guiding strategies involving immunotherapy and small-molecule inhibitors.